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Abstract: The drug/proton antiporter AcrB, engine of the major eﬄux pump AcrAB(Z)-TolC of
Escherichia coli and other bacteria, is characterized by its impressive ability to transport chemically
diverse compounds, conferring a multi-drug resistance (MDR) phenotype. Although hundreds of
small molecules are known to be AcrB substrates, only a few co-crystal structures are available to
date. Computational methods have been therefore intensively employed to provide structural and
dynamical fingerprints related to transport and inhibition of AcrB. In this work, we performed a
systematic computational investigation to study the interaction between representative carbapenem
antibiotics and AcrB. We focused on the interaction of carbapenems with the so-called distal pocket,
a region known for its importance in binding inhibitors and substrates of AcrB. Our findings reveal
how the different physico-chemical nature of these antibiotics is reflected on their binding preference
for AcrB. The molecular-level information provided here could help design new antibiotics less
susceptible to the eﬄux mechanism.
Keywords: antibiotic resistance; Gram-negative bacteria; resistance nodulation-cell division
transporters; AcrB; molecular docking; molecular dynamics simulations; binding free
energy calculations
1. Introduction
The increased number of MDR Gram-negative bacterial strains, along with the reduced efficacy
of available antibiotics, constitute a significant concern for public health [1–3]. A prominent role
in the MDR phenotype is played by resistance nodulation-cell division (RND) eﬄux pumps [4–12],
complex poly-specific transporters involved in the extrusion of a wide range of chemically unrelated
compounds. The inner membrane drug/proton antiporter AcrB, part of the major AcrAB(Z)-TolC eﬄux
system of Escherichia coli, is one of the most investigated members of the RND superfamily [6,13–19].
Structurally, AcrB is a homotrimer and each of its protomers is composed of a transmembrane (TM)
domain (where a proton gradient provides the energy needed for substrate translocation [20]), a porter
domain (responsible for the recognition, uptake, and first transport of substrates), and a funnel domain
(constituted by a channel linked to partner proteins AcrA and TolC) (Figure 1).
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Figure 1. View of the AcrB trimer. The access, binding, and extrusion protomers of AcrB are represented
as yellow, red, and ice blue ribbons, respectively. The inset shows a front and top magnification of the
porter domain of the T monomer of AcrB highlighting PN1, PN2, PC1, and PC2 subdomains and the
access and deep binding pockets represented as red and blue surfaces, respectively. The second inset
shows the main regions of interest discussed in this study, as reported in Table S1. The switch-loop and
the bottom loop are displayed as yellow and cyan tubes, respectively. HP-trap and exit gate residues
are shown as gray and orange sticks, respectively. Interface, groove, and cave residues are represented
as violet, green, and purple surfaces and lines respectively. Protein residues lining each region are
reported in Table S1.
Both a symmetric and an asymmetric conformation of AcrB, thought to represent its resting
and active states respectively, have been identified by X-ray crystallography [13,14,16,21–24]. In the
asymmetric structure, each protomer is found in a different conformational state defined as loose
(L), tight (T), and open (O) [13,18,19]. This finding suggested that the eﬄux of substrates is induced
by a functional rotation mechanism [13–15], where each protomer can alternatively assume the
above conformations in concert with the others. This hypothesis has been supported by subsequent
experimental [25,26] and computational studies [27–31]. Additionally, the available asymmetric
structures of AcrB allowed for the identification of specific substrate recognition sites: (i) the access
pocket (AP), located in the vestibule region between PC1 and PC2 subdomains and open in protomers
L and T [16,32]; (ii) the distal pocket [16,32], located more closely to the funnel domain and open only
in the T protomer (hereafter DPT; see Table S1 for the list of residues belonging to different regions of
AcrB). Recently, a new binding site localized in the transmembrane region has been identified [26].
Due to its crucial position in the entire eﬄux pathway, the DPT is supposed to interact with all AcrB
substrates along their transport pathway, independently of their molecular size and physico-chemical
features. This hypothesis has been recently supported by the publication of the co-crystal structures of
high molecular mass compounds bound within the DPT of MexB, the homologous protein of AcrB
in Pseudomonas aeruginosa [33]. The portion of the DPT comprising multiple phenylalanine residues
(136, 628, 610, 615, 628) and named “hydrophobic trap” (HP-trap) [34], is a crucial recognition site
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for AcrB inhibitors [35,36], and was also shown to interact with several substrates [16,32,37–39]. The
interface between access and distal pockets is constituted by a glycine rich loop (aka “switch loop”),
which regulates the transition of substrates towards the DPT [16,32,40]. A “bottom-loop”, which could
play a role as well in the recognition and transport of substrates, is found oppositely to the switch-loop
within the access pocket [40–42] (Figure 1).
A detailed understanding of the relationship between physico-chemical properties of antibiotics
and their propensity to be expelled by eﬄux pumps is relevant to understand the mechanisms of
polyspecific transport and can be very informative for drug design campaigns. Due to the complexity
of RND transporters and the difficulty of producing co-crystals, only a few X-ray structures of the
asymmetric trimer of AcrB bound to substrates have been reported to date [13–16,18,20,26,32,34].
The characteristics of compounds co-crystallized so far led to the conclusion that a certain degree of
hydrophobicity is required for substrates of AcrB [43]. Computational studies can provide atomistic
information on the dynamics of biomolecular complexes. As such, they represent a viable alternative
to gain insights into the binding of compounds to AcrB. One of the earlier studies on this protein
identified two distinct sub portions of the DPT, called “groove” and “cave” [44,45]. The groove region
is located in the upper portion of the DPT, close to the so-called exit gate (EG, Table S1) [15], while the
broader cave region is located at the bottom of the DPT. Later, molecular dynamics (MD) simulations
have been used to investigate substrate binding and specificity of AcrB [37,38,46], as well as to unveil
the link between structural-chemical fingerprints of compounds and physico-chemical properties of the
multidrug binding sites of AcrB [42,47]. These studies revealed that compounds can preferentially bind
to the cave, to the groove or to both regions, but no clear rules were identified explaining the binding
preferences of different compounds. Indeed, almost iso-energetic binding modes were predicted for
the same ligand, a result compatible with the so-called oscillation hypothesis [19], according to which
AcrB substrates oscillate between different binding modes with similar affinity within the DPT.
Among the different families of in-use antibiotics, carbapenems represent a primary resource
for the treatment of severe bacterial infections [48,49]. Unfortunately, several carbapenem-resistant
Gram-negative strains emerged over the years, for which there is evidence that these antibiotics can
be recognized and extruded by RND eﬄux pumps [50–52]. These conclusions usually relied on the
comparison between minimum inhibitory concentration (MIC) measurements obtained for wild-type
and eﬄux-pumps deficient strains. However, MIC values are strongly influenced by the interaction of
the drug with many other bacterial components: for instance, the membrane permeability, heavily
dependent on intrinsic drug properties, can definitely surpass the specific contribution of active eﬄux
to MDR [53,54]. As an example, while meropenem is a good substrate of the MexAB-OprM eﬄux
pump from P. aeruginosa and imipenem resistance to this organism appears to be predominantly caused
by changes in outer membrane pores, the impact of AcrAB-TolC on the activity of IMI and MER
in E. coli is still under debate [55]. In this context, direct eﬄux and affinity measurements [56–58],
combined with a molecular picture of the interaction between these compounds and AcrB, would be
pivotal for the design of more effective antibiotics starting from validated and widely used scaffolds.
Along these lines, we report here a comparative computational investigation of the interactions
between selected carbapenem antibiotics, such as biapenem (BIA), doripenem (DOR), ertapenem
(ERT), faropenem (FAR), imipenem (IMI), meropenem (MER), panipenem (PAN), and tomopenem
(TOM) (Figure 2), and the DPT of AcrB. Half of the selected carbapenems (namely DOR, ERT, IMI,
and MER) are currently in clinical use. As a reference, two eﬄux pump inhibitors (MBX3132 and
D13-9001, hereafter MBX and P9D respectively) and two known substrates of AcrB (rhodamine-6G
and minocycline, hereafter RDM and MIN) was investigated with the same computational protocol
adopted for carbapenems (Figure 2).
Int. J. Mol. Sci. 2020, 21, 860 4 of 15
Figure 2. Two-dimensional (2-D) structures of the substrates/inhibitors co-crystallized with AcrB and
of the selected carbapenems antibiotics considered in this study.
The outcomes of this work led to the identification of binding modes and specific interactions
between chemically related molecules and different sub-pockets within the DPT of AcrB. This study
contributes to explain the detailed interactions established by different carbapenem antibiotics with
the DPT of AcrB in terms of their intrinsic physico-chemical properties. A retrospective analysis of the
previous literature on other antimicrobial compounds [44] revealed the general applicability of our
findings [35,55,59–61].
2. Results
In continuation of our previous studies [37,55,59,60], we combined molecular docking, MD
simulations, binding free-energy and hydrophobic/hydrophilic surface-matching calculations, and
solvation analyses. Namely, for each compound, one single mode of binding within the DPT of AcrB was
found from blind docking calculations. These docking poses (and the crystallographic configurations
considered) were used as starting conformations for 100 ns-long all-atom MD simulations in water
solution followed by a cluster analysis of the trajectory. Binding free-energy calculations were thus
performed on the conformations extracted from the most populated conformational cluster. From
the cluster representative configuration, the hydrophobic (SML) and hydrophilic (SMH) matching
coefficients between the interaction surfaces of the compound and the DPT of AcrB were computed:
both quantities range from (no matching) to 1 (full matching). Additionally, the de-solvation of each
compound upon binding to AcrB was also estimated from MD simulations (see Materials and Methods
for details).
In the following paragraphs, we first present the results for substrates and inhibitors co-crystallized
with AcrB; next, we discuss the data obtained for the carbapenem antibiotics considered in this
work. The starting X-ray crystal configurations and the selected docking poses as well as the
structural cluster representative of each MD simulation can be visualized online at the web address
www.dsf.unica.it/translocation/docking. To rationalize our results in terms of specific physico-chemical
features of the compounds, we report some molecular properties in Table S2. Molecular weights (MWs)
are approximately in the range 300–500 Da, while the total charge ranges from -1 to +1 including several
neutral zwitterionic species. Based on available MICs data (compiled in Table S3), the AcrAB-TolC
eﬄux pump would recognize and expel the considered compounds. However, as specified in the
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Introduction, a detailed atomistic description of the interactions of different compounds within the
extrusion channel of AcrB cannot be achieved with current experimental techniques.
2.1. Substrates and Inhibitors Co-Crystallized with AcrB
Comparative data available for the crystallographic poses of substrates and inhibitors bound
to the DPT of AcrB are summarized in Table 1. Two substrates MIN (PDB ID: 4DX5 [32]) and RDM
(PDB ID: 5ENS [36]), and the two inhibitors P9D (PDB ID: 3W9H [34]) and MBX (PDB ID: 5ENQ [36])
were considered. MD simulations revealed overall stability of the crystallographic poses (Figure S1),
as further confirmed by the cluster analysis of the trajectory which predicted one single conformational
cluster in all cases. The root-mean-square displacement (RMSD) of the cluster representative from
the starting X-ray configuration has the value of 2.1, 4.0, 1.7, and 2.4 for MIN, RDM, MBX, and
P9D, respectively (Figure S2). The hydrophobic surface-matching analysis showed that the lipophilic
surface matching (SML) plays an important role in the interaction observed for all the compounds
(values between 0.80 and 0.96). On the contrary, the hydrophilic surface matching (SMH) is found to
vary from 0.01 (RDM) to 0.91 (P9D) according to the very different chemical nature of these compounds
as quantified by the octanol/water partition coefficient logP (Table S2).
Table 1. List of substrates and inhibitors co-crystallized with AcrB and considered in this study, along
with their molecular identifier and molecular weight (MW). The central columns report the hydrophobic
(SML), and hydrophilic surface matching (SMH), and the percentage of water molecules in the first
solvation shell (Hyd) calculated against molecular dynamics (MD) simulations of the corresponding
compound in water solution. The remaining columns report respectively the free energy of binding
(∆Gb) for the most populated cluster trajectory identified for each simulation, and the percentage
contribution to ∆Gb from residues lining the interface between access pocket and DPT, the cave, and
the groove regions of the DPT (see Figure 1 and residues list in Table S1).
Co-Crystallized
AcrB Compound ID
MW
(Da) SML SMH
Hyd
(%)
∆Gb
(kcal/mol)
Contribution to ∆Gb (%)
Interface Cave Groove
Rhodamine-6G RDM 444 0.80 0.01 35 ± 8 −38.3 ± 3.3 2 5 29
Minocycline MIN 458 0.80 0.70 34 ± 8 −29.3 ± 4.8 1 5 53
MBX3132 MBX 495 0.87 0.63 30 ± 8 −53.6 ± 4.6 2 18 24
D13-9001 P9D 693 0.96 0.91 40 ± 7 −52.3 ± 4.9 2 22 25
No clear trend was found between the dehydration of compounds and their classification as
substrates or inhibitors of AcrB (Table 1). Given the highly hydrophobic nature of the DPT, a consistent
fraction of waters was lost in all cases (from 60% to 70% compared to the value in bulk water).
As to the strength of the interaction, the inhibitors show higher affinities (larger negative values
of the binding free energy ∆Gb) in comparison to substrates. In order to investigate more deeply
the reason for this difference, we analysed the per-residue contributions to ∆Gb focusing on residues
lining three well-defined portions of the pocket so as to locate spatially the binding mode of each
compound: the entrance of the DPT (or the Interface between access pocket and DPT), and the cave
and groove regions defined in [44] (Table S1). The contribution to ∆Gb of the different regions of the
DPT reported in Table 1 reveal that: a) the interface turns out to contribute almost nothing (1–2%) to
the stabilization of both substrates and inhibitors; b) MIN and RDM appear to be prevalently groove
binders (contribution in the range 30–50%); c) MBX and P9D bind the entire pocket, interacting with
both the cave and the groove regions (energetic contribution of about 20% for both cave and groove).
The detailed pattern observed (Figure 3) reveals the prominent role played by PHE178, ILE277, VAL612,
and PHE615 (groove) in stabilizing the binding of all compounds, as well as the contribution of the
hydrophobic residues PHE136, VAL139, TYR327, VAL571, and PHE628 (cave) only to the stabilization
of inhibitors. Importantly, not only hydrophobic residues (especially the phenylalanines of the HP-trap),
but also polar (ARG620) and weakly polar (SER287) residues are found to be relevant. All of the above
findings are consistent with previous investigations [35,37] and available structural and biophysical
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data, validating the adopted computational protocol for a systematic investigation of the binding of
carbapenems to the DPT of AcrB.
Figure 3. Per-residue contributions to the free-energy of binding (kcal/mol) evaluated for the
considered substrates and inhibitors co-crystallized with AcrB. Only residues contributing more
than kT (~0.6 kcal/mol at 310 K) are reported. Residues of the interface, DPT cave and DPT groove are
colored with different tones of blue according to their individual contribution to the overall ∆Gb.
2.2. Carbapenems
Given the absence of experimental data concerning the molecular interaction of carbapenems with
the DPT of AcrB, the same computational investigation described for known inhibitors and substrates
of this transporter was performed for selected antibiotics of this family.
Table 2 summarizes the results obtained for the carbapenems, sorted by increasing MW. MD
simulations revealed that few compounds remained close to the starting configuration (MER, PAN, DOR,
see Figure S3), while consistent mobility was observed for the remaining compounds, with RMSDs
ranging from 4–5 Å (FAR, BIA, ERT) up to 5–6 Å (IMI, TOM). Contrary to what has been observed
for known substrates and inhibitors of AcrB, in the case of carbapenems the hydrophilic surface
matching seems to be more relevant than the lipophilic matching (on average, we found higher values
of SMH as compared to SML, and in 3 out of 8 cases the latter value almost vanishes). Measured
dehydration for carbapenems is similar to that observed for substrates and inhibitors only for FAR,
IMI and MER (60–70% of water molecules lost). The other members of the class show less pronounced
dehydration in the range 50–60%. The values of ∆Gb computed for carbapenems are of the same
order of magnitude as that of MIN (about -30 kcal/mol). Notably, in agreement with the results of
our previous study [55], MER displays a moderately higher affinity than IMI for the DPT of AcrB
(−31 vs. −25 kcal/mol), coupled with reduced mobility. Interestingly, some qualitative trends appear
when considering the different contributions to the total ∆Gb of the interface, the cave, and the groove
regions of the DPT. More specifically, the contribution of the interface, which was almost null for
known substrates and inhibitors, remains relatively small but roughly anti-correlated to the MW,
ranging from ~10% for the smallest compound to zero for the largest one. Except for DOR, MER,
and TOM, the contribution of the cave falls in the range 20–30%, on average exceeding the values
registered for inhibitors (~20%). On the contrary, while for smaller carbapenems the contribution of
groove residues is reduced (~5%), for bulkier compounds we observe the same order of magnitude
found for substrates and inhibitors (~30%). The only exception to the above trend is represented by
TOM, whose cave and groove contributions are similar and relatively small (~15%).
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Table 2. Structural and energetic features of the carbapenem-AcrB interaction. See Table 1 for details.
Carbapenem
Antibiotic ID
MW
(Da) SML SMH
Hyd
(%)
∆Gb
(kcal/mol)
Contribution to ∆Gb (%)
Interface Cave Groove
Faropenem FAR 284 0.45 0.81 27 ± 9 −25.5 ± 3.5 12 31 5
Imipenem IMI 299 0.11 0.21 37 ± 13 −25.1 ± 4.7 6 24 4
Panipenem PAN 339 0.01 0.80 50 ± 11 −27.6 ± 5.0 4 23 5
Biapenem BIA 350 0.04 0.60 45 ± 13 −30.5 ± 5.5 5 20 7
Meropenem MER 383 0.29 0.73 35 ± 8 −30.8 ± 4.3 1 15 29
Doripenem DOR 420 0.35 0.84 47 ± 10 −33.6 ± 5.5 0 14 33
Ertapenem ERT 475 0.30 0.51 42 ± 9 −33.8 ± 7.8 3 28 31
Tomopenem TOM 539 0.01 0.54 50 ± 9 −32.6 ± 6.7 0 15 12
The above analysis is complemented by the detailed per-residue contributions reported inFigure 4,
which reveal a thermodynamic pattern overall different from that shown in Figure 3 for known
substrates and inhibitors of AcrB. Firstly, for a few low-MW carbapenems a non-negligible contribution
to ∆Gb comes from some residues of the Interface region (PHE617 belonging to the switch-loop between
the AP and the DP, or THR91, MET573, and ILE626). Secondly, stabilization of low-MW carbapenems
appears to be due mostly to residues from the cave, including several hydrophobic but also polar and
charged sidechains. Thirdly, at increasing MW, the compounds appear to be more and more buried
within the whole DPT, stabilized by residues from both cave and groove residues (similar to what is
observed for some inhibitors [34,36]; see also Figure S4). Overall, PHE617 of the Interface, PHE136 and
ARG620 of the cave, and PHE178, ILE277, and PHE615 of the groove contribute mostly to the free
energy of binding of the carbapenems considered in this work.
Figure 4. Per-residue contributions to the free-energy of binding (kcal/mol) of carbapenems to AcrB.
See Figure 3 for further details.
As expected, consistently with the mainly lipophilic nature of the DPT, hydrophobic residues are
found to be the majority. Additional residues contributing to the stabilization of some carbapenems,
such as GLN89, SER135, TYR327, and ASN274, are known to play a key role in the eﬄux of substrates
mediated by AcrB [62].
3. Discussion
Despite the recognized role of RND eﬄux systems in multi-drug resistance to antibiotics,
a quantitative assessment of their contribution remains challenging due to the difficulties in
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the determination of the eﬄux kinetics of most substrates of AcrB and homologous RND
transporters [58,63,64]. While for other drugs the binding to AcrB has been characterized
structurally [32,34,36] and/or by means of site-directed mutagenesis [65–67] to the best of our knowledge
for the carbapenems investigated in this study, the available data possibly related to eﬄux-mediated
resistance are the variations in the MIC values of antibiotics upon deletion of the outer membrane
transporter TolC and/or AcrB (or homologous proteins see e.g., [68–70]). These data, however,
notoriously reflect additional processes involving antibiotics and other bacterial components [53].
Furthermore, the challenges of obtaining experimental structures of RND transporters in complex
with their substrates must be taken into account in this scenario [8]. Henceforth, several computational
labs made efforts at determining the molecular interactions between these multi-drug proteins and
different compounds, including antibiotics and inhibitors [37,42,44,47,71,72] (for a recent review,
see [73] and references therein). The work presented here can be framed in this context and was
motivated by the purpose of providing information about the possible interaction between selected
carbapenems and AcrB of E. coli. Indeed, to the best of our knowledge, no direct eﬄux measurements
are available for this class of compounds. In contrast, whereas kinetic eﬄux data are available for other
families of β-lactam antibiotics [58,63].
The binding propensity of carbapenems to the DPT of AcrB as well as their interaction patterns
revealed several remarkable features. First, along with the MD simulations, all compounds but
imipenem adopted a relatively stable (along the timescale of tens of ns) binding position within the DPT
of AcrB, regardless of the displacement from the initial docking pose (Figures S3 and S4). A comparable
dynamic behavior for imipenem (supposedly not an AcrB substrate) was observed in our previous
study [55]. Second, we found an interesting correlation between the MW of the compounds and their
binding preference to previously identified sub-pockets within the DP. Namely, the groove seems to
contribute to the binding of medium/high MW substrates, while smaller compounds tend to cluster
within the cave and interact marginally with the AP/DP Interface. The only exception to this rule
seems to be ertapenem, for which the cave and the groove contribute to a similar extent to the binding,
mostly because of a significant role of PHE178 for the stabilization of this compound. Tomopenem
turns out to be the compound for which the residues from groove, cave, and interface contribute less
to the binding. Third, another peculiar property for the carbapenems family highlighted by the MD
simulations, appears to be the ability of the drugs in the hydrophobicity screen of the DPT. The higher
SMH values found for the carbapenems in comparison to SML values (Table 2) indicate a preference for
a hydrophilic complementary interactions surface between the drug and the protein, although the
prevalent composition of the DPT is hydrophobic.
In a broader perspective, our findings are in agreement with previous results by Takatsuka and
Nikaido [44], who investigated the binding of a few dozen compounds to the DPT of AcrB. Even if
not explicitly mentioned by the authors, a link between the MWs of compounds and their binding
preference towards different regions of the pocket is detectable from the analysis of their data. Indeed,
we noticed that compounds such as doxorubicin, novobiocin, erythromycin, taurocholate, rifampicin,
etc., were predicted to be groove binders, while low-MW compounds such as chloramphenicol, SDS,
1-(1-naphthylmethyl)-piperazine, etc., were predicted to be cave binders. Therefore, the present
findings could represent a more general feature related to the mechanism by which AcrB achieves its
polyspecificity, namely the ability to accommodate for multiple substrates not only at different pockets
located in the different monomers of the transporter, but also at different sub-pockets within the same
multi-functional site [42,47].
Unfortunately, we were unable to find any additional parameter correlating with the binding
preferences of the carbapenems investigated in this work. However, with the limitations of the adopted
computational approaches in mind (such as insufficient sampling of the possible conformations of the
molecules within the DPT, intrinsic limitation of force fields in describing microscopic changes that
could happen within the pocket upon recognition and binding, to cite a few), in combination with
accurate assays to directly measure eﬄux of substrates [53,67,74–76], we believe that the computational
Int. J. Mol. Sci. 2020, 21, 860 9 of 15
protocol presented in this study represents a valuable source of information to experimentalist aiming
at rationalizing microbiological data.
4. Materials and Methods
4.1. Molecular Docking
Following the protocol adopted in previous investigations [55,59], we first performed an extensive
blind docking campaign using AutodockVINA (The Scripps Research Institute, La Jolla, CA, USA) [77]
by adopting a rectangular search space of size 125 × 125 × 110Å3 enclosing the whole portion of the
protein potentially exposed to ligands. Flexibility of both docking partners was considered indirectly,
by employing ensembles of conformations. For each compound, representative conformations obtained
from an explicitly solvated MD simulation of 1 µs were used (data available at www.dsf.unica.it/
translocation/db) [78], see also Table S2 for a list of some molecular properties). In all cases we
considered only the most populated charge/protonation state at physiological pH = 7.4 [78]. For the
receptor, conformations including X-ray structures as well as derived from µs-long MD simulations
were considered [42].
The choice of the initial conformations was limited to one pose within the DPT for all molecules.
Starting poses were selected according to the estimated binding affinity and the fraction of contacts
made by each molecule within the DPT (residues lining this region are listed in Table S1). We identified
the docking poses within the DPT as those in contact (3.5 Å cut-off distance) with at least 30% of the total
number of residues lining this site. In addition, the position and orientation of the molecules were also
taken into account to evaluate the effect on their behavior inside this region. The number of docking
poses identified for each compound according to this criterion, together with the corresponding
“average binding affinity” calculated from the scoring function of AutodockVINA [77] are reported in
Table S2. Importantly, a statistical contact analysis performed for compounds co-crystallized with AcrB
revealed how the adopted docking protocol was able to identify the relevant residues in contact with
the ligand in each of the X-ray structures considered (data not shown). The 2D interaction patterns of
the selected docking poses for each compound are shown in Figure S4.
4.2. MD Simulations and Binding Free-Energy Calculations
The initial coordinates of the AcrB-molecule complexes were taken from selected docking poses.
Due to the large number of compounds considered, we employed a reduced model of the AcrB protein
that does not contain the transmembrane domains, and consequently does not require modelling
the phospholipidic membrane. This model has been validated in previous studies [36,37]. Each
system was immersed in a box containing TIP3P water molecules [79] and an adequate number of
K+ counterions, in order to neutralize the negative net charge of the system. An osmolarity of 0.15 M
was reached by adding an appropriate number of K+/Cl−. The ff14SB version of the AMBER force
field [80] were adopted for AcrB, while the General Amber Force-Field parameters [81] adopted for
each molecule were taken from Ref. [78]. The systems were then minimized with a combination of
steepest descent and conjugate gradient methods gradually releasing positional restraints applied. The
AcrB/molecule complexes were heated from 0 to 310 K in two steps: a 1 ns heating from 0 to 100 K in a
canonical ensemble (NVT), followed by 5 ns heating to reach 310 K in an isothermal–isobaric ensemble
(NPT). Multiple equilibration steps of 500 ps each until the stabilization of the box dimensions were
performed in the NPT ensemble. A Langevin thermostat using a collision frequency of 1 ps−1 and
a Berendsen isotropic barostat [82] maintained a constant temperature, and an average pressure of
1 atm, respectively. A time step of 2 fs was used during the equilibration protocol. The 100 ns long
MD simulations were carried out using the PMEMD module of AMBER 18 (University of California,
San Francisco, CA, USA) [83] with a time step of 4 fs in the NVT ensemble, after application of the
hydrogen mass repartitioning [84]. Coordinates were saved every 100 ps. Long-range electrostatic
interactions were calculated using the particle mesh Ewald method with a cut-off of 9 Å [85]
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Root mean square deviations (RMSDs) were calculated using the cpptraj module of AMBERTools
and VMD (Beckman Institute, University of Illinois at Urbana-Champaign, USA) [86]. A cluster
analysis using the cpptraj module of AMBERTools identified the most populated configurations
sampled during the simulation with a fixed clustering radius of 3.5 Å. Only the most populated cluster
were further taken into account for evaluating the free energies of binding using the molecular mechanics
generalized Born surface area (MM-GBSA [87]) approach. The complementarity of the hydrophobic
and hydrophilic properties of the compounds and the DPT has been evaluated using PLATINUM
webserver [88]. A more detailed description of the MM-GBSA method and the hydrophobic surface
analysis implemented in PLATINUM can be found in the Supporting Information of Ref. [55,59]. The
starting X-ray crystal configurations and the selected docking poses as well as the “final” cluster
representative of each MD simulation can be visualized on-line through the NGL-viewer [89] at
www.dsf.unica.it/translocation/docking.
5. Conclusions
In this work we combined different computational techniques to investigate the interaction of
carbapenem antibiotics with the experimentally known periplasmic binding pocket DPT of AcrB, the
major eﬄux transporter from E. coli. Despite the acknowledged limitations, our protocol was able
to identify specific residues within the DPT of AcrB playing a prominent role in the binding affinity
of selected members of the carbapenem family. Importantly, this study allowed the identification of
subtle but relevant differences in compound/AcrB interactions, which can be hardly detected by other
means (namely MIC measurements). As such, it proved to be a precious tool to rationalize molecular
recognition of carbapenems by AcrB at an atomistic level. Specifically, we highlighted a correlation
between the molecular weight of compounds and their binding preference to previously identified
sub-pockets within the DPT, which could represent a general feature of the polyspecificity of AcrB.
Altogether, these pieces of information could help in the design of compounds that are less affected by
the activity of eﬄux pumps, or inhibitors able to hinder their function.
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